Open Access

Erratum to: ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms

  • D. James Morré1Email author,
  • Brandon Hostetler1,
  • David J. Taggart1,
  • Dorothy M. Morré1,
  • A. W. Musk2, 3, 4, 5,
  • Bruce W. S. Robinson2, 3, 4 and
  • Jenette Creaney2, 3
Clinical Proteomics201613:3

https://doi.org/10.1186/s12014-016-9105-1

Published: 22 February 2016

The original article was published in Clinical Proteomics 2016 13:2

Erratum to: Clin Proteom (2016) 13:2 DOI 10.1186/s12014-016-9103-3

It has come to the publisher’s attention that the original version of this article [1] unfortunately contained an unnecessarily complicated version of the data in Table 1. This Erratum replaces Table 1 of the original article with the table below.
Table 1

Range of molecular weights and isoelectric points (99th percentile) of ENOX2 transcript variants for 16 common cancer types compared with mesothelioma [Unpublished data from the ONCOblot Tissue of Origin Database, MorNuCo, Inc]

Cancer

N

Acceptable ranges

Protein 1

Protein 2

Protein 3

MW (kDa)

pI (pH)

MW (kDa)

pI (pH)

MW (kDa)

pI (pH)

Bladder

25

63–66

4.2–5.6

42–48

4.1–4.8

  

Blood cella

82

34–47

3.5–4.5

    

Breast

538

64–69

4.2–4.9

    

Cervical

37

90–100

4.2–5.4

    

Colorectal

90

80–96

4.4–5.4

50–65

4.2–5.3

33–46

3.8–5.2

Endometrial (uterine)

43

67–71

4.2–5.1

41–48

3.7–5.4

  

Gastric

10

120–188

4.7–5.5

50–62

4.5–5.6

45–53

2.4–3.6

Hepatocellular

19

58–70

4.5–5.0

34–40

4.1–5.2

  

Lung

200

52–56

4.1–5.3

    

Melanoma

39

37–41

4.6–5.3

    

Mesotheliomab

18

60–68

3.8–4.1

38–44

3.8–4.6

  

Ovarian

98

72–90

3.7–5.0

37–47

3.7–5.0

  

Pancreatic

61

49–51

3.9–5.4

    

Prostate

178

71–88

5.1–6.5

    

Kidney (renal cell)

21

69–73

4.7–5.4

54–61

4.1–5.2

38–43

3.7–4.3

Sarcoma

20

50–55

5.2–5.6

37–45

4.3–4.9

  

Squamous cell

41

57–68

5.0–5.4

    

Total

1520

      

aIncludes leukemia, lymphoma and myeloma

bPresent study

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
MorNuCo, Inc, Purdue University Research Park
(2)
National Centre for Asbestos Related Disease, University of Western Australia
(3)
School of Medicine and Pharmacology, University of Western Australia
(4)
Department of Respiratory Medicine, Sir Charles Gairdner Hospital
(5)
School of Population Health, University of Western Australia

Reference

  1. Morré DJ, Hostetler B, Taggart DJ, Morré DM, Musk AW, Robinson BWS, Creaney J. ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms. Clin Proteom. 2016;13:2.View ArticleGoogle Scholar

Copyright

© Morré et al. 2016

Advertisement